Active specific adjuvant immunotherapy with vaccinia melanoma oncolysate.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 1642396.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Vaccinia melanoma oncolysate is an investigative agent for active specific adjuvant immunotherapy. Viral oncolysate work in animals has led to application of this treatment in humans. Success of initial trials in treatment of melanoma has led to a phase III randomized, prospective, double-blind, multi-institutional trial, which is currently under way.
Medical subject headings
- Adjuvants, Immunologic
- Antigens, Neoplasm
- Antigens, Viral
- Immunotherapy, Active
- Melanoma
- Skin Neoplasms
- Vaccinia virus